Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Baune BT

Open source

DOI
10.1080/14622416.2026.2686866
Published
2026 May-Jun
Container
Pharmacogenomics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14622416.2026.2686866,
  title = {Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.},
  author = {Baune BT},
  year = {2026},
  journal = {Pharmacogenomics},
  doi = {10.1080/14622416.2026.2686866},
  url = {https://doi.org/10.1080/14622416.2026.2686866}
}

RIS

TY  - JOUR
TI  - Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.
AU  - Baune BT
PY  - 2026
JO  - Pharmacogenomics
DO  - 10.1080/14622416.2026.2686866
UR  - https://doi.org/10.1080/14622416.2026.2686866
ER  - 

APA

BT, B. (2026). Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.. Pharmacogenomics. https://doi.org/10.1080/14622416.2026.2686866

Source records